Review of prostate cancer diagnosis and treatment after the introduction of PSA screening: 1986-2005
Monday, November 30th, 2009 Posted in prostate cancer diagnosis | No Comments »Early detection and screening should identify cancers that will become clinically relevant. While early detection can be associated increases in incidence, raising the question of over-diagnosis, the number of individuals diagnosed with cancer would be unaffected by screening. Cancers that ...
Minimally Invasive Prostate Surgery Is Riskier
Sunday, November 29th, 2009 Posted in prostatectomy | No Comments »According to a study at Division of Urologic Surgery and the Center for Surgery and Public Health at Brigham and Women's Hospital, Boston, minimally invasive radical prostatectomy (MIRP) for prostate cancer (CaP) is the most common treatment modality for localized ...
Clusterin and prostate cancer
Saturday, November 28th, 2009 Posted in prostate cancer | No Comments »The role of clusterin (CLU) in prostate tumorigenesis is probably the most highly controversial, with evidence that CLU expression is increased or decreased in different cancer models. For example, some studies showed that CLU expression is increased in advanced stages ...
Report for prostate cancer therapeutics on the global market
Friday, November 27th, 2009 Posted in prostate cancer | No Comments »Reportlinker.com announces that a new market research report is available in its catalogue: Prostate Cancer Therapeutics - A Global Market Perspective Growth in prostate cancer therapies can be asociated to the increase in number of prostate cancer incidences in men aged ...
Unilateral prostate cancer cannot be accurately predicted in low-risk patients
Wednesday, November 25th, 2009 Posted in prostate cancer diagnosis | No Comments »Hemiablative therapy (HAT) is increasing in popularity for treatment of patients with low-risk prostate cancer (PCa). The validity of this therapeutic modality, which exclusively treats PCa within a single prostate lobe, rests on accurate staging. A new study at Prostate Cancer ...
GlaxoSmithKline withdraws its application for new drug use
Tuesday, November 24th, 2009 Posted in prostate cancer | No Comments »The world's No. 2 drugmaker, British company GlaxoSmithKline PLC, announced Monday it is temporarily withdrawing its application for U.S. approval of a drug to prevent prostate cancer. GlaxoSmithKline said it wants to provide an update to its application to the ...
Role of genistein in the prevention and treatment of prostate cancer
Monday, November 23rd, 2009 Posted in prostate cancer | No Comments »Tumor suppressor genes produce proteins that reduce the risk of normal cells becoming cancer cells. Therefore, when key tumor suppressor genes are silenced by hypermethylation, normal (benign) cells may become transformed into malignant cells. A new research study, just published in ...
Radical prostatectomy reigns supreme
Saturday, November 21st, 2009 Posted in prostatectomy | No Comments »A new study at Division of Urologic Surgery, Brigham and Women's Hospital, Boston, suggests the clinical incidence of prostate cancer continues to increase in the patient population, while the actual mortality has remained relatively low. As clinicians, we struggle to ...
Patient decision aids for prostate cancer treatment
Friday, November 20th, 2009 Posted in prostate cancer | No Comments »According to a recent study at University of California at San Francisco, treatment decision-making can be difficult and complex for patients with low-risk prostate cancer. To the researchers' knowledge, there is no consensus regarding an optimal treatment strategy and the choice ...
Experimental prostate cancer drugs tested in Belfast
Thursday, November 19th, 2009 Posted in Uncategorized | No Comments »Around 10,000 men in the UK die from prostate cancer each year. This is one of the reason Belfast City Hospital joins other leading research hospitals around the world in using the experimental drugs designed to help men whose cancer ...